1/2 We’re excited to announce our Industry Session keynote for the Immunity by Design: In Vivo Immune Cell Engineering Conference! Rachael Nimmo (former director of the Cell Technology Group at OXB).

1/2 The Immunity by Design: In Vivo Immune Cell Engineering Conference presents the Industry Session, featuring Lorenz Mayr (BioMedTech Consulting) Cristiana Pires (@AsgardThx ), and Sara Mangsbo (@uppsalauni).

1/2 The Immunity by Design: In Vivo Immune Cell Engineering Conferenceintroduces Session 3: Delivery Technologies & Translation, joining Alexandra Teleki (Uppsala University), Jai Prakash (Radboud University Medical Centre), and Samir El Andaloussi (Karolinska Institutet).

10) Combining the delivery of PIB mRNAs with miRNA mimics showed cooperative effects and initiated non-viral cDC1 reprogramming.

9) Importantly, miR-142 improved cancer cell reprogramming and enhanced anti-tumor immunity in vivo, leading to reduced tumor growth and increased survival rates.

8) Functionally, miR-142-enhanced cells produced more IFN-λ1, a cytokine strongly associated with cDC1 biology and anti-tumor immunity. We further identified TGFBR1 as a miR-142-regulated barrier to cDC1 reprogramming.

7) We then analyzed contribution of canonical and non-canonical miRNA products to cDC1 reprogramming. While miR-124-3p recapitulated miR-124’s effects, canonical miR-142 strands did not enhance cDC1 reprogramming. Instead, multiple 5′ isomiRs cooperated to achieve the phenotype.

6) Meanwhile, miR-124 acts by increasing chromatin accessibility and creating a permissive environment for the reprogramming factors PU.1, IRF8 and BATF3 (PIB) to activate cDC1 programs.

5) Mechanistically, miR-142 enhances reprogramming fidelity, repressing fibroblast identity and strengthening cDC1-specific programs. This is highlighted by increased expression of key cDC1 markers, including XCR1.

4) Two clear hits emerged: miR-124, which increased reprogramming efficiency; and miR-142, which improved cDC1 lineage fidelity. And these effects were conserved across mouse and human systems.

3) Despite what is known for other lineages, the role of miRNAs and isomiRs in immune cell conversions remains undefined. What did we do? We screened 15 candidate miRNAs for their role in type 1 conventional dendritic cell (cDC1) reprogramming.

1) 📢 New study out in @CellReports: We uncover how microRNAs (miRNAs) and their isoforms (isomiRs) regulate immune cell specification and reprogramming. Read it here: cell.com/cell-reports/fullte… A thread 🧵 #microRNA #reprogramming #immunotherapy

1/2 We’re thrilled to announce our fourth keynote speaker for Immunity by Design: In Vivo Immune Cell Engineering Conference! Willem Mulder (Radboud University Medical Center/ Eindhoven University of Technology) is a leading researcher in immune-imaging & precision immunotherapy.

1/2 We’re happy to announce our third keynote speaker for the Immunity by Design: In Vivo Immune Cell Engineering Conference! Sine Reker Hadrup (Technical University of Denmark) develops technological platforms to study T cell reactivity in disease contexts.

1/2 The Immunity by Design: In Vivo Immune Cell Engineering Conferenceintroduces Session 2: Synthetic Biology & Gene Editing, joining William Nyberg (Karolinska Institutet), Axel Hyrenius-Wittsten (Lund University), and Mirco Friedrich (DKFZ German Cancer Research Center).

1/2 The Immunity by Design: In Vivo Immune Cell Engineering Conference will have a dedicated @scilifelab session with Tina Catela Ivkovic (Center for Translational Genomics), Mikael Mattsson (Drug Discovery and Development), and Anahita Bakochi (BioMS).

1/2 The Immunity by Design: In Vivo Immune Cell Engineering Conference introduces Session 1: Cell Engineering & Reprogramming. Pereira lab will share stage with Judit Svensson Arvelund & Özcan Met to discuss emerging approaches in immune cell engineering & cancer immunotherapy.

1/2 We’re thrilled to announce Adi Barzel (Tel Aviv University) as a keynote speaker for Immunity by Design: In Vivo Immune Cell Engineering Conference! His work explores in vivo genome editing and strategies to engineer T and B cells for therapeutic applications.

1/2 We’re excited to announce our first keynote speaker for Immunity by Design: In Vivo Immune Cell Engineering Conference! Sai Reddy (ETH Zurich) works on engineering the immunogenome & reprogramming immune cells for applications in biotechnology, vaccination & immunotherapy.

1/2 Registration is OPEN for the Immunity by Design: In Vivo Immune Cell Engineering Conference!✨ Join us in Lund 22–23 Oct 2026 in a vibrant environment that brings together researchers from all career stages. #ImmuneEngineering #Immunotherapy #BiotechIndustry